Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.43) by 20.58 percent. This is a 3.17 percent decrease over losses of $(2.84) per share from the same period last year. The company reported quarterly sales of $6.878 million which beat the analyst consensus estimate of $6.100 million by 12.75 percent. This is a 183.16 percent increase over sales of $2.429 million the same period last year.